What's Happening?
Abbott CEO Robert Ford announced that the company is on track to launch its pulsed field ablation (PFA) system, Volt, in the U.S. next year. Despite competitors like Medtronic, Boston Scientific, and Johnson
& Johnson already debuting their PFA systems, Ford emphasized that Abbott is not late to the market. The Volt system, which received Europe’s CE mark in March, is expected to gain FDA approval in 2026. The system is designed to deliver deeper, more durable lesions with real-time contact visualization, potentially allowing procedures to be performed under conscious sedation rather than general anesthesia. Abbott's electrophysiology business, which includes PFA devices, saw a 15% increase in sales in the third quarter.
Why It's Important?
The introduction of Abbott's Volt PFA system represents a significant advancement in cardiac ablation technology, which is used to treat heart rhythm disorders. PFA is becoming the preferred method due to its potential for safer and faster procedures. Abbott's entry into this market could enhance its competitive position and drive growth in its electrophysiology business. Additionally, the company's diabetes business is preparing to launch a dual-analyte sensor that measures both glucose and ketones, which could help prevent diabetic ketoacidosis, a serious complication of diabetes.
What's Next?
Abbott is preparing for the launch of its Volt PFA system in the U.S. next year, with expectations of FDA approval in 2026. The company is also anticipating expanded Medicare coverage for its continuous glucose monitors, which could significantly increase market penetration. Abbott's strategic focus on innovative medical devices and expanding coverage could lead to substantial growth in its electrophysiology and diabetes businesses.
Beyond the Headlines
Abbott's developments in PFA and diabetes monitoring reflect broader trends in the medical device industry towards more precise and patient-friendly technologies. These innovations not only promise improved clinical outcomes but also align with healthcare's shift towards personalized medicine. As regulatory and market dynamics evolve, companies like Abbott are poised to play a pivotal role in shaping the future of medical technology.
